defence research and development canada, is looking for a researcher to conduct a prospective, observational cohort study of canadian armed forces (caf) personnel and veterans experiencing post-traumatic stress disorder (ptsd); using a multimodal neuroimaging (i.e., pet, mrs, mri) and multivariate biomolecular analysis approach, to assess brain and blood correlates of ptsd, which could yield both clinical utility and novel mechanistic insights into this condition. 

the canadian institute for military and veteran health research (cimvhr) has entered into partnership with the government of canada to procure research and development services related to the mental, social and physical wellbeing of active military members, veterans and their families.  cimvhr is seeking notices of interest from qualified researchers or a research team to enter into a contract with cimvhr to produce this work.

organizations that want to help seniors make a difference in the lives of others and in their communities are eligible to receive federal grants and contributions funding. projects must be led or inspired by seniors and address one or more of the following five program objectives:

• promoting volunteerism among seniors and other generations;
• engaging seniors in the community through the mentoring of others;
• expanding awareness of elder abuse, including financial abuse;
• supporting the social participation and inclusion of seniors; and
• providing capital assistance for new and existing community projects and/or programs for seniors.

organizations are allowed to submit multiple applications; however, the total of all applications combined must not exceed $25,000, including applicable taxes per year, per organization. otherwise, the organization will have to withdraw an application to respect the funding limit.

please contact the office of research no later than may 23 if you will be applying to this fund.

the career awards for medical scientists (cams) is a highly competitive program that provides $700,000 awards over five years for physician-scientists, who are committed to an academic career, to bridge advanced postdoctoral/fellowship training and the early years of faculty service.

connection grants support events and outreach activities geared toward short-term, targeted knowledge mobilization initiatives. these events and activities represent opportunities to exchange knowledge and to engage on research issues of value to those participating. events and outreach activities funded by a connection grant may often serve as a first step toward more comprehensive and longer-term projects potentially eligible for funding through other sshrc funding opportunities.

connection grants proposals are expected to meet the objectives of the connection program.

connection grants support workshops, colloquiums, conferences, forums, summer institutes or other events or outreach activities that facilitate:

• disciplinary and/or interdisciplinary exchanges in the humanities and social sciences;
• scholarly exchanges between those working in the social sciences and humanities and those working in other research fields;
• intersectoral exchanges between academic researchers in the humanities and social sciences and researchers and practitioners from the public, private and/or not-for-profit sectors; and/or
• international research collaboration and scholarly exchanges with researchers, 世界杯2022赛程表淘汰赛 and non-academic partners from other countries.

the rto/ero foundation is announcing a funding opportunity for research projects that focus on enhancing the quality of life of aging adults. this competition is open to qualified grantees based in ontario and british columbia.

guidelines

fy17 bmfrp program announcement and general application instructions for the following award mechanism are posted on grants.gov. 

as directed by the office of the assistant secretary of defense for health affairs, the defense health agency (dha) research and development directorate (j9) manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

idea development award – pre-application july 13, full application october 5

established investigators:  independent investigators at or above the level of assistant professor (or equivalent) and 10 years or more from a terminal degree; or

early career investigators:  investigators at the level of assistant professor, instructor, or assistant research professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible.

preproposal is required; full application submission is by invitation only.

·         supports innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the vision to understand and cure bmf.

·         strong bmf research team.

·         may include relevant preliminary data.

• clinical trials will not be supported.

·         maximum funding of $315,000 in direct costs (plus indirect costs)

• period of performance not to exceed 2 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcement and general application instructions that will be available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

applications must be submitted through the federal government’s single-entry portal, grants.gov.  for email notification when the program announcement is released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the bmfrp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

fy17 ocrp program announcements and general application instructions for the following award mechanisms are posted on grants.gov.

as directed by the office of the assistant secretary of defense for health affairs, the defense health agency (dha), j9 research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

the mission of the ocrp is to support patient-centered research to prevent, detect, treat, and cure ovarian cancer.  although not required, investigators are encouraged to address one of the fy17 areas of encouragement in their applications.

·         novel therapies and associated predictive biomarkers

·         non-invasive surveillance and assessment of disease

·         treatment resistance

·         immunotherapy

·         etiology, epidemiology, and prevention

·         early detection

·         rare subtypes

·         host-tumor interactions

·         survivorship and quality of life

clinical development award – pre-application due june 21, full application due september 11

must be an independent investigator at or above the level of assistant professor (or equivalent)

·     supports the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life.

·     near-term impact is expected.

·     preclinical studies in animals are not allowed.

·     small-scale clinical trials (phase 0, phase 1, pilot), studies enriching a clinical trial, and projects related to or associated with ongoing or completed clinical trials are allowed.

·     preliminary data are required.

pre-application is required; application is by invitation only.

maximum funding of $600,000 for direct costs (plus indirect costs)

maximum period of performance is 3 years

investigator-initiated research award – pre-application due june 21, full application due september 11

must be an independent investigator at or above the level of assistant professor (or equivalent)

·    supports meritorious basic and clinically oriented research in ovarian cancer.

·    impact is an important review criterion.

·    preliminary data are required.

·    clinical trials are not allowed. 

pre-application is required; application is by invitation only.

maximum funding of $450,000 for direct costs (plus indirect costs)

maximum period of performance is 3 years

ovarian cancer academy award – early-career investigator– pre-application due june 21, full application due september 6

must be within 3 years of his/her last postdoctoral research position (ph.d) or clinical fellowship (m.d.), or equivalent as of the full application submission deadline.  a letter attesting to eligibility is required.

·    supports the addition of new early-career investigators to the unique, interactive virtual academy that will provide intensive mentoring, national networking, and a peer group for junior faculty.

·    early-career investigators whose ability to commit to conducting ovarian cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.

·    a designated mentor who is an experienced ovarian cancer researcher with ovarian cancer funding is required.

·    the designated mentor is not required to be at the same institution as the early-career investigator.

·    preliminary data are required.

·    clinical trials are not allowed.

pre-application is required; application is by invitation only.

maximum funding of $725,000 for direct costs (plus indirect costs)

maximum period of performance is 4 years

pilot award– pre-application due june 14, full application due august 24

established investigator:  independent investigator for whom it has been more than 3 years since his/her last postdoctoral research position (ph.d) or clinical fellowship (m.d.), or equivalent; or
early-career investigator: 

investigators must meet one of the following criteria by the application submission date:

·  must be within 3 years of his/her last postdoctoral research position (ph.d) or clinical fellowship (m.d.).

or

·  in a postdoctoral research position (ph.d), or clinical fellowship (m.d.), or equivalent. 

a letter attesting to eligibility is required.

·    supports innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ovarian cancer research forward.

·    innovation and impact are important review criteria.

·    early-career investigator option supports applicants in the early stages of their research careers.  applications from early-career investigators and established investigators will be peer reviewed and compete for funding separately. 

·    goal is to develop preliminary data; thus, preliminary data are not required, but are allowed.

·    clinical trials are not allowed.

pre-application is required and is blinded; application submission is by invitation only.

maximum funding of $250,000 for direct costs (plus indirect costs)

maximum period of performance is 2 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions that will be available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

applications must be submitted through the federal government’s single-entry portal, grants.gov.  for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the ocrp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

fy17 alsrp program announcements and general application instructions for the following award mechanisms posted on the grants.gov website. 

as directed by the office of the assistant secretary of defense for health affairs, the defense health agency, research, development and acquisition (dha rda) directorate manages the defense health program (dhp) research, development, test and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcement/funding opportunity is the congressionally directed medical research programs (cdmrp).

therapeutic development award –pre-application due june 9, full application august 31

independent investigators at all academic levels

pre-application is required; full application submission is by invitation only.

supports post-discovery, preclinical development of therapeutics for als

preliminary data, including identify and purity of an identified bioactive compound(s), are required

types of efforts that will be supported include:

o   validation of lead pharmacological agents up to ind submission

o   optimization of potency and pharmacology, studies of formulation, stability and production methods based on good manufacturing practices

collaboration with industry is encouraged

clinical trials are not allowed

does not support screening or development of screens or models

maximum funding of $1,000,000 for direct costs (plus indirect costs)

maximum period of performance is 2 years

therapeutic idea award – pre-application due june 9, full application due august 31

independent investigators at all academic levels

pre-application is required; application submission is by invitation only.

supports hypothesis-driven drug discovery efforts focused on als therapeutics

preliminary data are not required

types of efforts that will be supported include:

o   novel exploitation of pathways known to be relevant to als for the purpose of improving treatment and/or advancing a novel treatment modality

o   development, validation and use of novel of high-throughput screens and model systems based on novel targets or innovative drug systems

o   development of methods for measuring engagement of mechanistic targets by drug candidates

innovation in technologies and techniques is an important criteria

maximum funding of $500,000 for direct costs (plus indirect costs)

maximum period of performance is 2 years characterization of mechanisms for the purpose of identifying new targets is outside of the scope of this announcement

a pre-application is required and must be submitted through the cdmrp electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.

full applications must be submitted through the federal government's single-entry portal, grants.gov. all applications must conform to the final program announcements and general application instructions that will be available for electronic downloading from grants.gov. the application package containing the required forms for each award mechanism can be found on grants.gov. a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org. for more information about the alsrp or other cdmrp administered programs, please visit the cdmrp website (http://cdmrp.army.mil).